Generative Artificial Intelligence refers to algorithms capable of creating new data instances that resemble existing data. In drug discovery, generative AI can be used to design novel chemical entities, biological sequences or molecular representations that satisfy predefined biochemical or pharmacological constraints. Unlike traditional approaches that rely on time-consuming high-throughput screening or structure-based rational design with limited chemical libraries, generative AI can propose novel candidates, enabling exploration of vast chemical spaces beyond human-curated libraries. Combined with other ML/AI methods, generative AI accelerates the challenging early stages of drug development.¹

Machine Learning for Drug Discovery: Foundations and Integration

Machine learning has become a foundational component of modern drug discovery, enabling data-driven analysis and prediction across the entire drug development pipeline. Early applications focused on quantitative structure–activity relationship (QSAR) modeling using algorithms such as linear regression, random forests and support vector machines. It was followed by deep learning approaches, including convolutional neural networks, graph neural networks and transformer-based models, capable of capturing non-linear relationships between molecular structure and biological activity. By streamlining target identification, virtual screening, property prediction and lead optimization, AI/ML significantly reduces experimental costs and timelines.²

Generative AI extends this capability by proposing novel candidates and is increasingly combined with predictive ML to form end-to-end drug discovery workflows. In other words, predictive models can rapidly assess the drug-like properties and safety of compounds generated by generative models. These workflows are often iterative, with reinforcement learning guiding molecular refinement to enable efficient exploration of chemical space under multiple constraints.²

What is Generative Artificial Intelligence in Drug Discovery?

Generative Artificial Intelligence in drug discovery encompasses machine learning models that learn the underlying distribution of molecular or biological data to generate previously unseen candidates. ³

Generative AI differs from traditional machine learning in both its objectives and its methodology. Conventional machine learning models primarily predict molecular properties or classify compounds based on labeled data. In contrast, generative models, such as variational autoencoders (VAEs) and generative adversarial networks (GANs), aim to create new data instances, allowing researchers to explore novel compounds rather than being constrained to existing libraries.⁴

In drug discovery, generative AI plays a critical role in de novo molecular design. By conditioning generation on specific objectives, such as target binding affinity, solubility or toxicity, these models can propose candidates optimized for multiple criteria simultaneously.⁴

How Generative AI Transforms the Drug Discovery Workflow

Generative AI is reshaping the drug discovery workflow by introducing data-driven design, optimization and decision-making across multiple stages of development.

De novo drug design:

Generative AI supports the creation of novel compounds tailored to specific disease targets by learning biologically relevant chemical structures and proposing molecules with desired properties. They can be used to design candidates through rapid exploration of therapeutically relevant structures, extending beyond existing chemical libraries.⁵

Lead optimization

During lead optimization, generative AI refines promising drug candidates by navigating the latent chemical space or iteratively modifying molecular structures, thereby optimizing binding affinity, solubility and toxicity. This accelerates the transition from hit compounds to high-quality leads while reducing the number of experimental cycles.⁶

Target Identification and Validation

AI plays a critical role in identifying and validating drug targets by analyzing large-scale biological, multi-omics and structural datasets. Machine learning models integrate genomic, transcriptomic, proteomic and interactome data to uncover novel disease pathways and prioritize targets with strong mechanistic and clinical relevance. These algorithms inform the starting point for de novo drug design.⁷

Preclinical and clinical development

During the preclinical development of generative AI-driven compounds, AI models predict pharmacokinetic behavior, toxicity and off-target effects, which are critical for the early identification of high-risk compounds. Furthermore, during clinical development, machine learning guides patient stratification and trial design to enhance the likelihood of clinical success.⁸

Regulatory Review

Generative AI and machine learning can support regulatory review by improving data consistency, traceability and interpretability across the drug development process. AI-driven analyses aid in documenting decision-making, assessing risk and monitoring safety signals, contributing to more transparent and evidence-based regulatory submissions.⁸

Core Technologies Behind Generative AI in Drug Discovery

Deep Learning Architectures

The most frequently used generative models are as follows:

• Variational autoencoders (VAEs) encompass an encoder that learns a probabilistic latent space, which captures hidden relationships across complex molecular and epidemiological datasets. It uses this map to smoothly extrapolate a set of novel molecules that are continuous transformations of known compounds.⁹
• Generative adversarial networks (GANs) comprise a generator that creates candidate molecules and a discriminator that evaluates their realism, leading to progressively improved molecular designs.¹⁰
• Reinforcement learning models frame molecule design as a sequential decision-making problem, where molecular structures are constructed step by step to maximize a defined reward function. Rewards typically reflect desired properties such as target affinity, synthetic feasibility or safety profiles.¹¹
• More recent architectures, such as diffusion models and transformer-based generators, further enhance stability, scalability and control over molecular generation and optimization.⁴

Foundation Models and Large Biological/Chemical Models

Large-scale language models treat chemical structures, sequences or reactions as “languages” and learn patterns across vast datasets. These models can predict molecular properties, suggest novel compounds and capture hidden rules directly from data. Structural prediction models forecast protein folding or protein–ligand interactions, providing detailed insights into target–ligand binding, guiding rational drug design and improving the prioritization of candidate molecules.¹²

Integrating Machine Learning for Drug Discovery with Experimental Data

Successful drug discovery requires tight integration of AI predictions with experimental validation. Iterative cycles involve AI-driven predictions or novel drug design, followed by laboratory experiments to evaluate and validate AI outputs and feed experimental results back into the models for recalibration. The success of such a tightly coupled workflow depends on both the robustness of computational models and the quality of experimental procedures^.13

Benefits of Generative AI in Drug Development

The benefits of generative artificial intelligence in drug discovery can be summarized as follows:¹³

• Speeding up the drug discovery timeline and reducing the financial burden associated with extensive experimental workflows
• Expanding chemical space exploration beyond the traditional limits of existing compound libraries
• When integrated with predictive machine learning models, this can increase precision in predicting molecule-target interactions
• Contributing to large compound libraries and promoting collaboration across research disciplines through AI platforms

Applications of Generative AI for Drug Discovery

Generative AI has found broad applications across multiple domains of drug discovery, including small-molecule design, biologics, biomarker discovery and laboratory operations.

Small-Molecule Development

Generative AI for small-molecule drug discovery supports the rapid design of novel compounds with favorable drug-like properties and synthetic feasibility. Generative models can optimize novel compounds across multiple attributes, such as potency, selectivity, solubility and safety, ultimately accelerating lead identification.¹⁴

Biologics and Protein Engineering

Generative AI can also be applied to the design of biologics, including antibodies and other protein-based therapeutics. Models trained on large protein sequence and structure datasets accelerate de novo antibody design, optimizing affinity and specificity. It guides the design of engineered protein therapeutics by capturing sequence–structure–function relationships.¹⁵

Biomarker Identification and Stratification

Generative and predictive AI models can analyze high-dimensional multi-omics and clinical data to identify disease subgroups and predict treatment responses based on the molecular signatures of each subgroup. Therefore, AI-driven approaches are essential for precision medicine and for clinical trial design^.16

Workflow Automation and Laboratory Optimization

Through workflow automation, generative AI models can be integrated with laboratory data collection and analysis systems. AI-driven automated platforms coordinate data preprocessing, experiment planning and result interpretation, improving reproducibility across experimental pipelines. Thus, laboratory resources can be used more effectively to validate generative artificial intelligence models in drug discovery.¹³

Challenges and Considerations of Gen AI in Drug Discovery

Many of the technical, regulatory and ethical challenges encountered in predictive machine learning for drug discovery apply to generative AI.¹

The reliability of generative models depends heavily on the quality, diversity and representativeness of the chemical and biological data used for training. Incomplete, biased or noisy datasets can lead to the overrepresentation of well-studied targets or chemical structures, limiting generalization^.1

Regulatory compliance poses additional challenges for AI-driven drug discovery. Agencies require clear documentation of data provenance, decision-making and model validation, which is a limitation of generative AI algorithms. The limited transparency of generative models complicates risk assessment, underscoring the need for standardized validation and reporting practices.¹

These challenges are closely related to ethical considerations. Generative AI systems must be thoroughly evaluated to ensure that de novo compounds proposed by the model are scientifically sound and representative of realistic data.¹⁷

References

1. Gangwal A, Ansari A, Ahmad I, Azad AK, Kumarasamy V, Subramaniyan V, et al. Generative artificial intelligence in drug discovery: basic framework, recent advances, challenges, and opportunities. Front Pharmacol 2024;15:1331062.
2. Koirala M, Yan L, Mohamed Z, DiPaola M. AI-Integrated QSAR modeling for enhanced drug discovery: from classical approaches to deep learning and structural insight. Int J Mol Sci 2025;26(19):9384.
3. Bian Y, Xie X-Q. Generative chemistry: drug discovery with deep learning generative models. J Mol Model 2021;27(3):71.
4. Farhadi A, Zamanifar A, Faezipour M. Application of Generative AI in Drug Discovery. Application of Generative AI in Healthcare Systems: Springer; 2025:155-174.
5. Tong X, Liu X, Tan X, Li X, Jiang J, Xiong Z, et al. Generative models for de novo drug design. J Med Chem 2021;64(19):14011-14027.
6. Zhang O, Lin H, Zhang H, Zhao H, Huang Y, Hsieh C-Y, et al. Deep lead optimization: leveraging generative AI for structural modification. J Am Chem Soc 2024;146(46):31357-31370.
7. Kang SI, Shin JH, Wu BM, Choi HS. Deep Generative AI for Multi-Target Therapeutic Design: Toward Self-Improving Drug Discovery Framework. Int J Mol Sci 2025;26(23):11443.
8. Bordukova M, Makarov N, Rodriguez-Esteban R, Schmich F, Menden MP. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opin Drug Discov 2024;19(1):33-42.
9. Anusha K, Rani M, Satvika B, Tarun P, Vaishnavi G, Raju SL. Molecule Generation of Drugs Using VAE. Proceedings of the International Conference on Computational Innovations and Emerging Trends (ICCIET 2024): Springer Nature; 2024:170.
10. Rathod V, Gadilohar J, Pawar S, Joshi A, Sawant S. Unlocking new possibilities in drug discovery: a GAN-based approach. Artificial Intelligence-based Healthcare Systems: Springer; 2023:135-144.
11. Bou A, Thomas M, Dittert S, Navarro C, Majewski M, Wang Y, et al. ACEGEN: Reinforcement learning of generative chemical agents for drug discovery. J Chem Inf Model 2024;64(15):5900-5911.
12. Chakraborty C, Bhattacharya M, Pal S, Chatterjee S, Das A, Lee S-S. Ai-enabled language models (LMs) to large language models (LLMs) and multimodal large language models (MLLMs) in drug discovery and development. J Adv Res 2025.
13. Doron G, Genway S, Roberts M, Jasti S. Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D. Drug Discovery Today 2025;30(1):104272.
14. Kanakala GC, Devata S, Chatterjee P, Priyakumar UD. Generative artificial intelligence for small molecule drug design. Curr Opin Biotechnol 2024;89:103175.
15. Callaway E. How generative AI is building better antibodies. Nature 2023;617(7960):235-235.
16. Garg S. The Role of Generative AI in Personalized Medicine and Treatment Recommendations. CMHRJ 2025;5(02):1214-1227.
17. Bhadra S, Pundir C, Mukherjee M, Kar A, Banerjee S, Charoensup R, et al. Reimagining ethnopharmacology with generative AI: Towards inclusive, ethical, and data-driven traditional medicine. Pharmacol Res 2025:108002.